Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,586 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06499350RecruitingPhase 1/Phase 2
New combo for advanced solid tumors after standard therapy
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06351527RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has returned
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
Plantation, FloridaAges 18 years+ - NCT07299747RecruitingPhase 1/Phase 2
Study of VBC103 for advanced solid tumors
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07480005Recruiting
Staging laparoscopy for liver, pancreas, and bile duct cancers
This trial is checking how well a minimally invasive surgery (staging laparoscopy) detects the spread of liver, pancreas, or bile duct cancers before a bigger surgery. It may help doctors decide if a full operation is the right next step.
New Delhi, National Capital Territory of DelhiAges 18 years+ - NCT06181032RecruitingPhase 1
Immunotherapy and chemo combo before surgery for bile duct cancer
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Fuzhou, FujianAges 18–75 - NCT06943677RecruitingPhase 1
Testing TQB3019 for advanced blood cancers
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06930651RecruitingPhase 1/Phase 2
Engineered NK cell therapy for relapsed blood cancers
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Houston, TexasAges 18–80 - NCT07670949Recruiting
68Ga-EV203 imaging for blood cancers
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hangzhou, ZhejiangAges 18–75 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06823609RecruitingPhase 1
Study of QLS-1304 for advanced solid tumors
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07340190RecruitingPhase 1
How pelabresib affects other drugs in advanced cancer
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
Candiolo, TOAges 18 years+ - NCT07230665Enrolling by invitation
Comparing two procedures for stomach blockage from cancer
This trial compares two ways to treat blockage at the end of the stomach caused by cancer: a stent (a small metal tube) or a newer endoscopic bypass. The goal is to see which works better for patients who cannot have surgery.
TaipeiAges 18 years+ - NCT07397819RecruitingPhase 1/Phase 2
Liposomal Irinotecan for Malignant Ascites
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
Guangzhou, GuangdongAges 18 years+ - NCT07240974RecruitingEarly Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
WuhanAges 18 years+ - NCT07207707RecruitingPhase 1
KQB548 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
La Jolla, CaliforniaAges 18 years+ - NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT00242723Recruiting
Looking at cell changes in lung, esophagus, and chest cancers
This study collects blood, urine, and tissue samples from people with lung, esophageal, or other chest cancers to look at cell changes. It does not test a new treatment—instead, it aims to better understand these cancers through research.
Bethesda, MarylandAges 2–120 - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Margate, FloridaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,586 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.